|
Work done
1. Intercountry
Consultative Meeting for Elimination of Visceral Leishmaniais, Varanasi, India,
November 2003. ( more information)
2. Regional
Technical Advisory Group was established and
the first meeting was held in Manesar, Gurgaon, India,
from 20-23 December 2004 (more
information)
3. Memorandum
of Understanding for Intercountry Cooperation
for kalaazar elimination signed by Health Ministers of India , Bangladesh and Nepal
in May 2005, in Geneva.
4. Inter-country
meeting of National Programme Managers for Kala-azar Elimination, Behror,
Rajasthan, India,1-2 September 2005
5. 2nd
meeting of RTAG in Nepal
6. Kolkata
meeting
7. Advocacy
materials to promote the endorsement of elimination of kala azar by decision makers in the endemic
countries and by the donors and stakeholders.
8. Partnerships
with several organizations World Bank, UNICEF, ADB, DFID, GTZ, JICA, USAID
and Bill and Melinda Gates Foundation and others considering support for the
elimination of kala azar and TDR to promote basic and implementation research
on drugs and diagnostics.
9. New
tools are available for early diagnosis (‘rk39’) and treatment (oral drug
Miltefosine). New drug Lipid Amphotericin B is in the horizone. It is safe
and highly effective in a single IV dose.
10. Three
countries have developed National Plan to eliminate kala azar and have
implemented the strategy for elimination in the pilot districts. India has implemented in the three affected states.
11. Implementation
research has been initiated by TDR and the three affected countries.
Future Plan
1. Development of Technical Guidelines
Following the development of standards and standard
operating procedures, WHO will develop and distribute necessary generic
guidelines and tools to programme managers. They will include: comprehensive
guidelines on elimination of kala-azar; guidelines on preparation,
implementation and monitoring of the programme; guidelines for preparing
country strategic plan for elimination of kala-azar; training guidelines on
diagnosis and case management, guidelines for home care and environmental
management with the focus on improving the home and peridomestic environment;
indoor residual spraying for health staff and volunteers to be involved in
the elimination of kala-azar, and surveillance guidelines on disease
occurrence and vector.
2. Drug
Quality, Drug Supply and Logistics
WHO will develop standards of quality for drugs and
laboratory supplies, guidelines on monitoring the quality of drugs, efficacy
of drugs and drug resistance and diagnostic kits. These will be made
available to national authorities.
3. Geographic
Information System Mapping for IRS
WHO will provide assistance to Member States through
training of staff to do geographical mapping in affected districts. The
health mapper is proposed to be used.
4. Technical
Support at Local Levels
WHO will provide technical support for programme
management and implementation at local levels (district and sub-district) by
NPO/State Coordinator/District Coordinator (Consultants) etc. depending on
the needs of individual countries and the resources that are available.
5. Research
Protocols and Capacity Development in Operational Research
WHO/SEARO will work with TDR and WHO collaborative
centres and research institutions to decide research priorities and support
the development of research protocols. It will assist in the development of
research capacity in countries. Networking of research through multicentric
research and research coordination mechanism would be facilitated.
|
